Teplizumab - preventative approaches to type 1 diabetes mellitus

被引：0
|
作者：
Seewoodhary, Jason [1 ]
Silveira, Angela [2 ]
机构：
[1] NHS Northwest London, Brent Integrated Hlth Board, London, England
[2] Saskatchewan Hlth Author, Publ Hlth & Prevent Med, Saskatoon, SK, Canada
来源：
PRACTICAL DIABETES | 2023年 / 40卷 / 02期
关键词：
teplizumab; type 1 diabetes mellitus; immunotherapy; anti-CD3; screening; INSULIN; TRIAL;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Immunotherapies offer the potential to reprogramme the immune system to halt autoimmune destruction of insulin-producing beta-cells within the pancreas, dealing with the root cause of type 1 diabetes (T1DM) for the first time. Leading on from this, teplizumab, the first drug in this class, has been found to delay the onset of T1DM by an average of three years in people stratified high risk for developing T1DM. This review will critically consider the evidence basis underlying the utility of teplizumab in the management of T1DM. Copyright (c) 2023 John Wiley & Sons.
引用
收藏
页码：35 / +
页数：5
相关论文
共 50 条
  • [31] Type 1 Diabetes Mellitus
    Gregory, Justin M.
    Moore, Daniel J.
    Simmons, Jill H.
    PEDIATRICS IN REVIEW, 2013, 34 (05) : 203 - 215
  • [32] Type 1 diabetes mellitus
    不详
    MEDICINA DELLO SPORT, 2007, 60 (03) : 337 - 343
  • [33] Type 1 diabetes mellitus
    Kaufman, FR
    PEDIATRICS IN REVIEW, 2003, 24 (09) : 291 - 299
  • [34] Type 1 Diabetes Mellitus
    Lee, Myung-Shik
    Kim, Kyoung -Ah
    JOURNAL OF THE KOREAN MEDICAL ASSOCIATION, 2009, 52 (07): : 677 - 687
  • [35] Cell-based immunomodulatory therapy approaches for type 1 diabetes mellitus
    Black, Labe
    Zorina, Tatiana
    DRUG DISCOVERY TODAY, 2020, 25 (02) : 380 - 391
  • [36] Type 1 diabetes mellitus
    Larger, E
    Dubois-Laforgue, D
    Timsit, J
    PRESSE MEDICALE, 1999, 28 (34): : 1895 - 1903
  • [37] Type 1 diabetes mellitus
    Katsarou, Anastasia
    Gudbjornsdottir, Soffia
    Rawshani, Araz
    Dabelea, Dana
    Bonifacio, Ezio
    Anderson, Barbara J.
    Jacobsen, Laura M.
    Schatz, Desmond A.
    Lernmark, Ake
    NATURE REVIEWS DISEASE PRIMERS, 2017, 3
  • [38] Safety and efficacy of teplizumab in the treatment of type 1 diabetes mellitus: An updated systematic review and meta-analysis of randomized controlled trials
    Alves, Gabriel Grando
    Cunha, Luisa
    Machado, Rafael Henkes
    de Menezes, Vanessa Lins
    DIABETES OBESITY & METABOLISM, 2024, 26 (07): : 2652 - 2661
  • [39] An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes
    Herold, Kevan C.
    Bundy, Brian N.
    Long, S. Alice
    Bluestone, Jeffrey A.
    DiMeglio, Linda A.
    Dufort, Matthew J.
    Gitelman, Stephen E.
    Gottlieb, Peter A.
    Krischer, Jeffrey P.
    Linsley, Peter S.
    Marks, Jennifer B.
    Moore, Wayne
    Moran, Antoinette
    Rodriguez, Henry
    Russell, William E.
    Schatz, Desmond
    Skyler, Jay S.
    Tsalikian, Eva
    Wherrett, Diane K.
    Ziegler, Anette-Gabriele
    Greenbaum, Carla J.
    NEW ENGLAND JOURNAL OF MEDICINE, 2019, 381 (07): : 603 - 613
  • [40] NivolumabFulminant type 1 diabetes mellitus and type 1 diabetes mellitus: 2 case reports
    Reactions Weekly, 2017, 1654 (1) : 254 - 254
12345